Search results

Order by most recent / most popular / relevance

Results: 1-10 of 82

Teva Canada Innovation v. Attorney General of Canada

Borden Ladner Gervais LLP
-
Canada
-
May 8 2013

The Patented Medicine Prices Review Board (the PMPRB) ordered Teva to pay the Crown approximately $2.4 million for selling its product at an

U.K. jumps on “pay-to-delay” bandwagon

Fish & Richardson PC
-
United Kingdom, USA
-
April 24 2013

The U.K. Office of Fair Trading ("OFT") jumped on the "pay-to-delay" bandwagon last week when it issued a "Statement of Objections," indicating a

Generics demand brand drug samples for ANDA filings

Fish & Richardson PC
-
USA
-
April 11 2013

Tensions between branded pharma companies and their generic competitors are boiling over into court battles over the "right" of generics to demand

Northern exposure?

Gowling Lafleur Henderson LLP
-
Canada, USA
-
April 4 2013

Davit Akman and John Norman suggest that a recently commenced investigation into alleged "product switching" and statements by the Interim

Supreme Court hears arguments in FTC v. Actavis

Banner & Witcoff Ltd
-
USA
-
March 27 2013

On March 25, 2013, the Supreme Court heard oral arguments in Federal Trade Commission v. Actavis, a case involving a circuit split regarding "pay for

Supreme Court hears oral argument in pay-for-delay patent settlement antitrust case

McDermott Will & Emery
-
USA
-
March 26 2013

The Supreme Court's ruling in Federal Trade Commission v. Actavis, Inc., will almost certainly have major implications for the viability of Federal

Pre-launch activities by generic companies: patent law and unfair competition

Gómez-Acebo & Pombo Abogados
-
Spain
-
March 13 2013

The Spanish courts have previously dealt with the question of whether specific pre-launch activities carried out by generic companies in the context

Watson and reverse payments: an opportunity to resolve the competing tension between antitrust and patent law under the Hatch-Waxman Act

Proskauer Rose LLP
-
USA
-
March 8 2013

On March 25, the Supreme Court will hear arguments in Federal Trade Commission v. Watson Pharmaceuticals, Inc., and take a step toward concluding

Abuso del sistema de patentes y de los procedimientos para la comercialización de medicamentos a fin de impedir o retrasar la entrada en el mercado de medicamentos genéricos competidores

Gómez-Acebo & Pombo Abogados
-
European Union, Spain
-
March 4 2013

En el presente documento se da cuenta de la relevante Sentencia de la Sala Primera del Tribunal de Justicia de la Unión Europea, de 6 de diciembre del

FTC v. Actavis: an analysis

Briggs and Morgan
-
USA
-
February 25 2013

In my view, the approach embodied in K-Dur strikes the right balance in terms of preserving patent incentives, on the one hand, and fulfilling the

next >

Search results

Teva Canada Innovation v. Attorney General of Canada

U.K. jumps on “pay-to-delay” bandwagon

Generics demand brand drug samples for ANDA filings

Northern exposure?

Supreme Court hears arguments in FTC v. Actavis

Supreme Court hears oral argument in pay-for-delay patent settlement antitrust case

Pre-launch activities by generic companies: patent law and unfair competition

Watson and reverse payments: an opportunity to resolve the competing tension between antitrust and patent law under the Hatch-Waxman Act

Abuso del sistema de patentes y de los procedimientos para la comercialización de medicamentos a fin de impedir o retrasar la entrada en el mercado de medicamentos genéricos competidores

FTC v. Actavis: an analysis

Current Search

Suggested Facets

Author

Firm Name

Jurisdiction

Workarea